Cargando…

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

PURPOSE. The aim of this study was to investigate whether progression‐free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in malignant mesothelioma. MATERIALS AND METHODS. Individual data were collected from 15 Cancer and Leukemia Group B (615 patients) and 2 North C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaofei, Wang, Xiaoyi, Hodgson, Lydia, George, Stephen L., Sargent, Daniel J., Foster, Nate R., Ganti, Apar Kishor, Stinchcombe, Thomas E., Crawford, Jeffrey, Kratzke, Robert, Adjei, Alex A., Kindler, Hedy L., Vokes, Everett E., Pang, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2017
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330706/ https://www.ncbi.nlm.nih.gov/pubmed/28188257 http://dx.doi.org/10.1634/theoncologist.2016-0121

Ejemplares similares

Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung cancer: a pooled analysis based on individual patient data of CALGB/Alliance trials
por: Yang, Lexie Zidanyue, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics
por: Gunatilake, Samal, et al.
Publicado: (2021)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database
por: Anggondowati, Trisari, et al.
Publicado: (2020)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)
por: Fuchs, Michael A., et al.
Publicado: (2014)

Treatment Paradigms for Advanced Non‐Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
por: Aggarwal, Charu, et al.
Publicado: (2017)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Tumor volume is an independent predictor of survival in patients with malignant pleural mesothelioma
por: Kircheva, Diana Y, et al.
Publicado: (2015)

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
por: van Kooten, Job P, et al.
Publicado: (2022)

Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)
por: Lee, Seohyuk, et al.
Publicado: (2021)

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
por: Clive, Amelia O, et al.
Publicado: (2014)

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
por: Møller, Henrik, et al.
Publicado: (2018)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Household disposable income and long-term survival after pulmonary resections for lung cancer
por: Sachs, Erik, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
por: Poad, Heather, et al.
Publicado: (2022)

Surviving White-out: How to Manage Severe Noninfectious Acute Lung Allograft Dysfunction of Unknown Etiology
por: Trindade, Anil J., et al.
Publicado: (2022)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
por: Fadelu, Temidayo, et al.
Publicado: (2018)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oral7451k4o3rvabcu5dhljco4